Muscat: Women’s health is being transformed and further prioritised with the launch of Organon (NYSE: OGN), the only global company of its size focused on women’s health. With the aim of improving the standard of living for women in Oman and supporting the future of healthcare, Organon goes beyond traditional focus areas of women health and deliver impactful medicines & solutions based on unique patient needs.
Managing Director Ramy Koussa of MENAT (Middle East, North Africa, and Turkey) in Organon, highlights the vision of the company, “As the MENAT region continues to grow and is expected to expand further in the coming years, we recognize the need to focus on women-specific health conditions and treatments that impact the everyday life of women. This launch will not only transform women’s healthcare but will also create over 400 job opportunities across MENAT. With our expertise, products, and technology in women-related conditions, we want to influence change in the region and empower women to take charge of their health to live better lives.”
The Organon executive leadership team rang the opening bell at the New York Stock Exchange (NYSE) to mark the first day of active trading. Recognising the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE sharing powerful perspectives, voices and images.
Dr Hanan Abdullah Al Mahrooqi, Senior Consultant Family Physician and Head of Bausher Specialised Polyclinic said, “Women are the spinal cord of the family and the primary caregiver to all members, giving good care to her is giving the care to the whole community”. Women everywhere are invited to take the “microphone” to add their voice to the digital “Wall of Voices” at www.HereForHerHealth.com.
Organon Oman’s Lead, Razan Gharaibeh said, “A unique offering that we are bringing to Oman to best cater to the unique needs of women includes biosimilars. In line with our commitment to increasing medical accessibility to women, biosimilars play a crucial role in reducing cost pressure on the healthcare system and provide more access to biological therapies. We will always be here for her health for a healthier woman, every day.”
The three core pillars that lead Organon’s offerings in Oman include:
Biosimilars: Actively building a strong foundation by broadening the reach of offerings into new geographies while expanding through new collaborations and into new disease areas.
Women’s Health: With more than 140 therapies that are being investigated by multiple companies across the women’s health industry, our goal is to add value by identifying and advancing the most promising opportunities for women.
Established Brands: Our portfolio of over 60 medicines span several areas including cardiovascular disease, respiratory conditions, non-opioid pain management and dermatology. This diverse set of products and trusted brands are critical drivers of Organon’s growth that will enable us to invest in new opportunities.
Organon has an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately $6.5 billion in annual revenue generated outside the US Organon believes it is well-positioned for organic low-to-mid-single digit growth from its 2021 base of business. Their approach to innovation is led by patient needs and the use of extensive global capabilities in clinical development and patient safety with the greatest potential to impact women’s health.
Sandy Milligan, Head of Organon Research & Development stated, “Women have been told to accept and normalise their conditions as a part of like, Organon’s mission is to change this. We believe this approach will be very successful — we hope to discover the ability to identify diseases earlier, the ability to modify the course of diseases or healthcare conditions and ultimately, improve the quality of life for women at all stages.”